[Clinical efficacy of zolmitriptan in migraine]. / Eficacia clínica de zolmitriptán en la migraña.
Neurologia
; 13 Suppl 2: 16-24, 1998 Oct.
Article
en Es
| MEDLINE
| ID: mdl-9859691
Zolmitriptan (previously known as 311C90) is a serotoninergic 5-HT1B/D agonist with high oral bioavailability with a double, central and peripheral, action mechanism. Evaluation of its clinical efficacy was developed in a program of clinical studies (search and confirmation of dosis, comparative and long term studies) and through analysis of efficacy in different clinical situations. Zolmitriptan shows a high effectiveness in the treatment of migraine crisis, significantly reduces the headaches by 2 hours of its administration, reduce the symptoms associated with migraine (nausea, photophobia and phonophobia) and improves the quality of life of the migraine patient. The efficacy is independent of the type of migraine characteristics of the patient as well as of the administration of other concomitant medications. The dosis of 2.5 mg of zolmitriptan has been found to be the optimum considering both efficacy and tolerability.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Oxazoles
/
Agonistas de Receptores de Serotonina
/
Oxazolidinonas
/
Trastornos Migrañosos
Aspecto:
Patient_preference
Límite:
Adolescent
/
Adult
/
Aged
/
Humans
/
Middle aged
Idioma:
Es
Revista:
Neurologia
Asunto de la revista:
NEUROLOGIA
Año:
1998
Tipo del documento:
Article
Pais de publicación:
España